DEMPDHPCA-2C-D
| Clinical data | |
|---|---|
| Other names | 2C-D-DEMPDHPCA; "Compound 45" | 
| Drug class | Possible serotonergic psychedelic or hallucinogen | 
| ATC code | 
 | 
| Identifiers | |
| 
 | |
| Chemical and physical data | |
| Formula | C20H30N2O3 | 
| Molar mass | 346.471 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
DEMPDHPCA-2C-D is a possible serotonergic psychedelic of the phenethylamine and 2C families. It is a cyclized phenethylamine and a partial or simplified lysergamide. More specifically, the compound is a derivative of 2C-D in which the β position has been cyclized with the amine to form a pyridine ring, an LSD-like N,N-diethylcarboxamide moiety has been added to the pyridine ring, and an N-methyl group has been added to the amine. Alternatively, it may be viewed as an analogue of LSD in which the atoms at positions 1 through 4 of the ergoline ring system have been removed and 4-methyl and 2,5-dimethoxy substitutions have been added to the phenyl ring (i.e., the A ring of LSD).
DEMPDHPCA-2C-D was synthesized and described by David E. Nichols in his thesis in 1973. Its pharmacology was not reported. However, several close analogues of DEMPDHPCA-2C-D, such as DEMPDHPCA and a few of its derivatives, have been reported to be potent serotonin 5-HT2A receptor agonists or to produce hallucinogen-like behavioral effects in animals. In addition, the established putative psychedelic LPH-5 is very similar to DEMPDHPCA-2C-D in chemical structure but most notably lacks the LSD-like N,N-diethylcarboxamide moiety.